IRRAS Q3: Relatively in line with our expectations - Redeye

Redeye embraces another quarter of continuous sales growth and key activities in its clinical trial progressions but notes a lingering uncertainty in COGS and the need for cash. We believe the coming +12 months will offer an opportunity for IRRAS to demonstrate its commercial progress and increase interest among investors once its balance sheet is once again strengthened. We adjust our fair value range based on the assumption of an equity issue in late 2023e.

Länk till analysen i sin helhet: https://www.redeye.se/research/862947/irras-q3-relatively-in-line-with-our-expectations?utm_source=finwire&utm_medium=RSS